推进急性呼吸窘迫综合征的精准医学
急性呼吸窘迫综合征(ARDS)是一种异质性临床综合征,尽管对肺损伤机制的理解不断深入,但仅靶向通气诱导肺损伤的疗法被证实有效,发病率和死亡率仍高。2019年美国国立心肺血液研究所召开多学科专家研讨会,探讨加速ARDS精准医学的研究机遇与挑战,总结研讨会讨论、建议及未解决问题。
要点
- ARDS具有临床和生物学异质性,可能影响治疗反应性。
- 精准医学方法旨在将疗法匹配给最可能获益的亚组患者。
- 研讨会讨论了临床前模型、队列研究和临床试验新方法。
核心结论
- ARDS精准医学旨在通过匹配疗法与预期最可能获益的患者亚组来更好地考虑异质性。
主要发现
- 仅靶向通气诱导肺损伤的疗法被一致证实有益,但ARDS发病率和死亡率仍高。
- 许多临床前有希望的候选疗法在人体试验中无效,可能部分由于临床和生物学异质性改变了治疗反应性。
临床怎么用
- 精准医学策略可考虑在临床试验中评估治疗效应异质性以初步识别获益亚组。
局限性
- 研讨会发生在COVID-19大流行之前。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Acute respiratory distress syndrome (ARDS) is a heterogeneous clinical syndrome. Understanding of the complex pathways involved in lung injury pathogenesis, resolution, and repair has grown considerably in recent decades. Nevertheless, to date, only therapies targeting ventilation-induced lung injury have consistently proven beneficial, and despite these gains, ARDS morbidity and mortality remain high. Many candidate therapies with promise in preclinical studies have been ineffective in human trials, probably at least in part due to clinical and biological heterogeneity that modifies treatment responsiveness in human ARDS. A precision medicine approach to ARDS seeks to better account for this heterogeneity by matching therapies to subgroups of patients that are anticipated to be most likely to benefit, which initially might be identified in part by assessing for heterogeneity of treatment effect in clinical trials. In October 2019, the US National Heart, Lung, and Blood Institute convened a workshop of multidisciplinary experts to explore research opportunities and challenges for accelerating precision medicine in ARDS. Topics of discussion included the rationale and challenges for a precision medicine approach in ARDS, the roles of preclinical ARDS models in precision medicine, essential features of cohort studies to advance precision medicine, and novel approaches to clinical trials to support development and validation of a precision medicine strategy. In this Position Paper, we summarise workshop discussions, recommendations, and unresolved questions for advancing precision medicine in ARDS. Although the workshop took place before the COVID-19 pandemic began, the pandemic has highlighted the urgent need for precision therapies for ARDS as the global scientific community grapples with many of the key concepts, innovations, and challenges discussed at this workshop.
引用
- Beitler JR, Thompson BT, Baron RM, et al. Advancing precision medicine for acute respiratory distress syndrome. Lancet Respir Med. 2021. PMID: 34310901. doi:10.1016/S2213-2600(21)00157-0
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。